Allergen Or Component Thereof (e.g., Ragweed Pollen, Etc.) Patents (Class 424/275.1)
-
Patent number: 8349333Abstract: Compositions and kits for inhibiting an allergic response against an allergenic protein are disclosed. The compositions comprise a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein; and an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein. The kits comprise a first container which comprises a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein and a second container which comprises an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein.Type: GrantFiled: December 22, 2006Date of Patent: January 8, 2013Assignees: China Agricultural University, WyethInventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
-
Patent number: 8343503Abstract: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of birch pollen Bet v 1. Such peptides while providing all potential T cell epitopes are devoid of the 3D structure of the original allergen, therefore reducing their ability to bind IgE.Type: GrantFiled: February 9, 2010Date of Patent: January 1, 2013Assignee: Anergis S.A.Inventors: Christophe Reymond, Francois Spertini
-
Patent number: 8343512Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: October 20, 2011Date of Patent: January 1, 2013Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20120321665Abstract: A composition for treating an airway inflammatory disease having high molecular weight, crosslinked hyaluronan and at least one aeroallergen is provided. A method of inducing immune tolerance to one or more aeroallergens in a mammalian subject suffering from or at risk of developing an airway inflammatory disease, and a method of treating a human subject suffering from or at risk of developing an airway inflammatory disease or condition of the lungs are also provided.Type: ApplicationFiled: June 14, 2012Publication date: December 20, 2012Applicant: BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASONInventors: Paul Bollyky, Gerald T. Nepom, Michael G. Kinsella
-
Patent number: 8333980Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.Type: GrantFiled: November 13, 2008Date of Patent: December 18, 2012Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
-
Publication number: 20120315264Abstract: Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.Type: ApplicationFiled: December 12, 2011Publication date: December 13, 2012Applicant: The Brigham and Women's Hospital, Inc.Inventors: Arthur O. Tzianabos, Dennis L. Kasper
-
Patent number: 8329144Abstract: A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.Type: GrantFiled: November 3, 2006Date of Patent: December 11, 2012Assignee: Isis Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Patent number: 8329196Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: GrantFiled: April 4, 2008Date of Patent: December 11, 2012Assignees: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette R. Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Patent number: 8329185Abstract: The invention relates to a method for quickly and effectively isolating and purifying five, namely the group 1, 2, 3, 10 and 13 allergens from grass pollen. The purification of said grass pollen is based on the inventive combination of hydrophobic interaction chromatography, gel filtration and cation exchange chromatography. The proteins obtained by the inventive method facilitate an improved diagnosis of pollen allergies and are used in pharmaceutical preparations for the therapy of pollenogenic diseases.Type: GrantFiled: December 13, 2007Date of Patent: December 11, 2012Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Roland Suck, Oliver Cromwell, Helmut Fiebig
-
Publication number: 20120301498Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.Type: ApplicationFiled: April 27, 2012Publication date: November 29, 2012Applicant: Selecta Biosciences, Inc.Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
-
Publication number: 20120294894Abstract: An object of the present invention is to provide a pharmaceutical composition that allows stable storage and delivery of heat-labile allergens. The present invention provides a pharmaceutical composition containing: an allergen; and at least one selected from the group consisting of an organic acid salt, an inorganic acid salt, and a pH adjuster.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: NITTO DENKO CORPORATIONInventors: Daisuke ASARI, Mitsuhiko HORI, Takuya SHISHIDO
-
Publication number: 20120294888Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.Type: ApplicationFiled: April 27, 2012Publication date: November 22, 2012Applicant: Selecta Biosciences, Inc.Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
-
Publication number: 20120294893Abstract: The present invention aims to provide a jelly (as a result, easy-to-swallow), intraorally soluble edible jelly composition although it is preferably free of water. The present invention relates to an edible jelly composition including: a gelling agent; and a nonvolatile organic solvent compatible with the gelling agent.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: NITTO DENKO CORPORATIONInventors: Daisuke ASARI, Takuya SHISHIDO, Mitsuhiko HORI, Kyohei MATSUSHITA
-
Publication number: 20120288527Abstract: An agent having antiallergic effects is provided, which is easily produced and ingested. A solvent extract of green soybean is used as an antiallergic agent. A solvent extract of green soybean having the effect of suppressing IgE production and the effect of shifting the Th1-Th2 balance to the Th1 side is useful as an antiallergic agent.Type: ApplicationFiled: December 28, 2009Publication date: November 15, 2012Applicants: SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORPORATION, NISSHIN PHARMA INC.Inventors: Mamoru Isemura, Akihiro Kaneko, Kensuke Yasui
-
Publication number: 20120288526Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.Type: ApplicationFiled: February 24, 2011Publication date: November 15, 2012Applicant: Merck Patent GmbHInventors: HELMUT FIEBIG, ANDREAS NANDY, ROLAND SUCK, OLIVER CROMWELL, ARND PETERSEN, WOLF-MEINHARD BECKER
-
Publication number: 20120276140Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: April 26, 2012Publication date: November 1, 2012Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Publication number: 20120276155Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.Type: ApplicationFiled: April 27, 2012Publication date: November 1, 2012Applicant: Selecta Biosciences, Inc.Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
-
Patent number: 8287875Abstract: Isolated nucleic acids encoding an allergen of Dermatophagoides pteronyssinus, Der p III, are disclosed. A cDNA encoding a peptide having a Der p III activity and a predicted molecular weight of about 24,985 daltons is also described. The nucleic acids can be used as probes to detect the presence of Der p III nucleic acid in a sample or for the recombinant production of peptides having an activity of Der p III. Peptides having an activity of Der p III can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to house dust mites.Type: GrantFiled: January 15, 2010Date of Patent: October 16, 2012Assignee: Merck Patent GmbHInventors: Wayne R. Thomas, Kaw-Yan Chua, Bruce L. Rogers, Mei-Chang Kuo
-
Publication number: 20120258140Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.Type: ApplicationFiled: June 12, 2012Publication date: October 11, 2012Applicant: COLEY PHARMACEUTICAL GMBHInventors: Marion Jurk, Jorg Vollmer
-
Patent number: 8277813Abstract: The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have. The polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.Type: GrantFiled: October 31, 2007Date of Patent: October 2, 2012Inventors: Edmond Godfroid, Yves Decrem, Luc Vanhamme, Alex Bollen, Gérard Leboulle
-
Patent number: 8263090Abstract: The present invention relates to the preparation and use of variants of the group 1 allergens of the Poaceae (sweet grasses) which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially maintained reactivity with T-lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventive immunotherapy of grass pollen allergies.Type: GrantFiled: July 11, 2005Date of Patent: September 11, 2012Assignee: Merck Patent GmbHInventors: Helmut Fiebig, Martin Wald, Andreas Nandy, Helga Kahlert, Bernahrd Weber, Oliver Cromwell
-
Patent number: 8246945Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: GrantFiled: October 2, 2009Date of Patent: August 21, 2012Assignees: University of Arkansas, Mount Sinai School of Medicine of New York University, Allertein Therapeutics, LLCInventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
-
Publication number: 20120207815Abstract: The present invention relates to the treatment of EE. More specifically, the invention relates to a new method of treating EE through the epicutaneous route. In particular, the method of the invention comprises applying to the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device and to a use of the skin patch device in the manufacture of a composition for treating eosinophilic esophagitis in a subject.Type: ApplicationFiled: March 6, 2012Publication date: August 16, 2012Inventors: Pierre-Henri Benhamou, Lucie Mondoulet
-
Publication number: 20120207788Abstract: The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.Type: ApplicationFiled: September 9, 2010Publication date: August 16, 2012Applicant: BIOMAY AGInventors: Rudolf Valenta, Birgit Linhart, Margarete Focke-Tejkl, Angela Neubauer, Peter Valent, Katharina Blatt
-
Publication number: 20120201807Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.Type: ApplicationFiled: February 24, 2012Publication date: August 9, 2012Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar R. Kandimalla
-
Publication number: 20120177701Abstract: Immunostimulatory compositions include an isolated nucleic acid molecule that includes one or more nucleotide sequences from 5?- or 3?-terminal regions of positive-sense, single-stranded RNA virus genomes and/or or nucleotide sequences from a 5?-terminal regions of negative-sense, single-stranded RNA virus genomes.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Applicant: SELECTA BIOSCIENCES, INC.Inventors: Petr O. Ilyinskii, Grayson B. Lipford
-
Publication number: 20120171251Abstract: The present invention provides a sheet-form preparation that can be easily dissolved intraorally, allows the dissolution time thereof to be easily controlled, and can stably contain an allergenic protein from cedar pollen. The sheet-form preparation contains water, gelatin, an allergenic protein from cedar pollen, and a stabilizing agent of the allergenic protein from cedar pollen.Type: ApplicationFiled: December 8, 2011Publication date: July 5, 2012Applicant: NITTO DENKO CORPORATIONInventors: Daisuke ASARI, Takuya SHISHIDO, Mitsuhiko HORI, Toshihiko OKAZAKI, Tatsuya KONISHI
-
Publication number: 20120148626Abstract: The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.Type: ApplicationFiled: June 7, 2010Publication date: June 14, 2012Applicant: STALLERGENES S.A.Inventors: Philippe Moingeon, Thierry Batard, Bertrand Villet
-
Publication number: 20120141536Abstract: The present invention relates to the use of a seasonal allergen composition for the manufacture of a vaccine formulation for preventing or treating allergy to the allergen composition in a subject by parenteral administration, wherein the vaccine formulation is administered in a dosage regimen comprising an up-dosing phase, wherein the up-dosing phase partly or wholly overlaps with the allergen season of the allergen composition.Type: ApplicationFiled: March 28, 2008Publication date: June 7, 2012Applicant: ALK-ABELLÓ A/SInventor: Eike Gunther Wustenberg
-
Publication number: 20120135020Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: ApplicationFiled: May 10, 2010Publication date: May 31, 2012Applicant: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Wantanabe
-
Patent number: 8187613Abstract: The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-?. The allergy prevention method or treatment method is to orally administer 100 ?g/kg or more of transforming growth factor-beta (TGF-?) relative to a weight of an administration target body and thereby selectively suppress Th2 immune response, while with respect to the diets and oral drugs, the content is set to contain an effective amount of transforming growth factor-beta (TGF-?) therein.Type: GrantFiled: December 15, 2009Date of Patent: May 29, 2012Assignee: Yamanashi UniversityInventor: Atsuhito Nakao
-
Publication number: 20120128597Abstract: A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.Type: ApplicationFiled: August 14, 2009Publication date: May 24, 2012Applicants: Forschungszentrum Borstel, Protectimmun GmbHInventors: Marcus Peters, Marion Kauth, Albrecht Bufe, Otto Holt
-
Publication number: 20120128699Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.Type: ApplicationFiled: November 18, 2011Publication date: May 24, 2012Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
-
Patent number: 8182822Abstract: The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-?. The allergy prevention method or treatment method is to orally administer 100 ?g/kg or more of transforming growth factor-beta (TGF-?) relative to a weight of an administration target body and thereby selectively suppress Th2 immune response, while with respect to the diets and oral drugs, the content is set to contain an effective amount of transforming growth factor-beta (TGF-?) therein.Type: GrantFiled: December 15, 2009Date of Patent: May 22, 2012Assignee: Yamanashi UniversityInventor: Atsuhito Nakao
-
Publication number: 20120121648Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.Type: ApplicationFiled: January 30, 2012Publication date: May 17, 2012Applicant: COLEY PHARMACEUTICAL GMBHInventors: Marion Jurk, Jorg Vollmer
-
Publication number: 20120121539Abstract: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.Type: ApplicationFiled: August 2, 2010Publication date: May 17, 2012Applicant: President and Fellows of Harvard CollegeInventors: Roger Warren Sands, Eduardo Alexandre Barros e Silva, Toshihisa Kawai, David J. Mooney
-
Publication number: 20120121688Abstract: The present invention provides a method of selectively augmenting an immunosuppressive function in various functions of NKT cells, and a method of efficiently inducing an antigen specific immunosuppression in vivo, as well as a pharmaceutical obtained by applying the same. More particularly, the present invention provides a pharmaceutical (e.g., a preventive or therapeutic agent for immune diseases such as allergic disease and autoimmune disease) containing a CD1d ligand and a target antigen (e.g., allergen, autoantigen). Preferably, the pharmaceutical contains a drug delivery vehicle including the CD1d ligand and the target antigen and having a lumen.Type: ApplicationFiled: January 12, 2007Publication date: May 17, 2012Inventors: Yasuyuki Ishii, Risa Nozawa, Yukiko Matsui
-
Publication number: 20120114699Abstract: Modified allergens having reduced allergenicity compared to corresponding native allergenic material, wherein all or a part of the primary amine groups of the lysine and arginine residues of the allergenic molecules are functionalized and the modified allergens have the structure wherein R and R2 are independently selected from H, C1-C5 alkyl, phenyl, phenyl substituted in ortho, meta, or para with a hydroxy, C1-C4 alkoxy, halogen, amino, alkylamino, dialkylamino, mercapto, C1-C4 alkylmercapto group; X represents O, S, or NR3, where R3 is H, alkyl with 1-6 carbon atoms, phenyl, or CN; R1 represents H, alkyl with 1-8 carbon atoms, phenyl or arylalkyl with up to 8 carbon atoms, or alkyl containing a heterocyclic ring; prot represents the protein residue of the allergen; n is the number of functionalized arginine groups and ranges between 1 and the number of arginine groups present in the allergen; m is the number of functionalized lysine groups and ranges between 1 and the number of lysine groups present inType: ApplicationFiled: October 2, 2009Publication date: May 10, 2012Applicant: LOFARMA S.P.A.Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Stefania Zanotta, Paolo Falagiani, Pietro Falagiani
-
Publication number: 20120087870Abstract: The present invention relates to the provision of a nucleic acid molecule encoding a Caviidae allergen comprising a polynucleotide selected from the group consisting of (a) a polynucleotide sequence as shown in SEQ ID NO 1 (Cav p 3), SEQ ID NO 5 (Cav p 2), SEQ ID NO 3 (Cav p 6) or SEQ ID NO 19 (Cavia porcellus allergen 1 a) or a fragment thereof, (b) a polynucleotide sequence encoding a polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 (Cavia porcellus allergen 1 a) or a fragment thereof (c) a polynucleotide sequence which has at least 80% identity to the polynucleotides as defined in (a) or (b) encoding a Caviidae allergen or a fragment thereof, (d) a polynucleotide sequence encoding a polypeptide which has at least 85% identity to the polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 (Cavia porcellus allergen 1a) or a fragment thereof, (e) a polynucleotide sequence which hybridizes to the polyType: ApplicationFiled: December 18, 2009Publication date: April 12, 2012Inventors: François Hentges, Christiane Hilger
-
Patent number: 8153414Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: GrantFiled: December 6, 2000Date of Patent: April 10, 2012Assignee: Allertein Therapeutics, LLCInventors: Michael J. Caplan, Hugh A. Sampson, A. Wesley Burks, H. Kim Bottomly, Howard B. Sosin
-
Publication number: 20120076825Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).Type: ApplicationFiled: December 7, 2011Publication date: March 29, 2012Applicant: ALK-ABELLO A/SInventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vázquez, Juan Carlos Moreno Segura, Maria José Chamorro Salillas
-
Publication number: 20120076831Abstract: The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.Type: ApplicationFiled: January 20, 2010Publication date: March 29, 2012Inventors: Stephen Miller, Russell L. Bromley, Michael A. Pleiss, Daniel Getts, Aaron Martin
-
Publication number: 20120076826Abstract: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.Type: ApplicationFiled: June 4, 2010Publication date: March 29, 2012Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20120070460Abstract: The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which utilise such molecules.Type: ApplicationFiled: September 16, 2009Publication date: March 22, 2012Applicant: Natural Environment Research CouncilInventors: Jon Austyn, Stephen Preston, Patricia Nuttall, Guido Paesen
-
Publication number: 20120064144Abstract: The present invention relates to the treatment of eczema. More specifically, the invention relates to a new method of treating eczema through the epicutaneous route. In particular, the method of the invention comprises applying to a non eczematous area of the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device.Type: ApplicationFiled: September 12, 2011Publication date: March 15, 2012Inventors: Pierre-Henri Benhamou, Christophe Dupont, Lucie Mondoulet, Vincent Dioszeghy
-
Publication number: 20120058147Abstract: Implementations and techniques for providing geographically region specific allergy immunotherapy for companion animals are generally disclosed.Type: ApplicationFiled: September 8, 2010Publication date: March 8, 2012Inventor: Jonathan D. Plant
-
Patent number: 8128935Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.Type: GrantFiled: June 11, 2003Date of Patent: March 6, 2012Assignee: Merck Patent GmbHInventors: Helmut Fiebig, Andreas Nandy, Roland Suck, Oliver Cromwell, Arnd Petersen, Wolf-Meinhard Becker
-
Patent number: 8105605Abstract: Provided is a pharmaceutical composition comprising tyrosine, an optionally modified allergen, and 3-DMPL, which is useful in the prevention and treatment of allergies.Type: GrantFiled: March 29, 2010Date of Patent: January 31, 2012Assignee: Allergy Therapeutics (UK) Ltd.Inventors: Jorj Terry Ulrich, Alan Worland Wheeler
-
Publication number: 20120014978Abstract: The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.Type: ApplicationFiled: November 27, 2009Publication date: January 19, 2012Applicant: CIRCASSIA LIMITEDInventors: Roderick Peter Hafner, Paul Laidler
-
Publication number: 20120009210Abstract: Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.Type: ApplicationFiled: July 8, 2011Publication date: January 12, 2012Applicant: BIOMAY AGInventors: Raffaela Campana, Rudolf Valenta, Susanne Vrtala, Ines Swoboda, Anna Gieras, Susanne Spitzauer, Peter Valent, Katharina Blatt, Margarete Focke-Tejkl, Birgit Linhart, Dietrich Kraft